Which peptide injections are used for weight loss?
A peptide is a short chain of amino acids — smaller than a protein but capable of binding to specific receptors and triggering targeted biological responses. Several peptides interact with pathways that directly or indirectly affect body weight: appetite signaling, metabolic rate, insulin regulation, and growth hormone secretion.
The key distinction in evaluating peptide injection for weight loss is between peptides that directly suppress appetite and caloric intake (GLP-1 receptor agonists) and those that support body composition through hormonal optimization (sermorelin and related growth hormone secretagogues). Both have legitimate clinical uses, but they work differently and suit different clinical pictures.
Why are GLP-1 receptor agonists the highest-evidence option?
Semaglutide and tirzepatide represent the peptide injections for weight loss with the most robust clinical trial evidence. Both are GLP-1 receptor agonists — they activate the receptor for glucagon-like peptide-1, a gut hormone that regulates satiety and gastric emptying.
How they work
By activating GLP-1 receptors in the brain and gut, semaglutide and tirzepatide reduce appetite, slow the rate at which the stomach empties, and diminish the preoccupation with food that many people with excess weight experience. The result is reduced caloric intake sustained over months — not through willpower but through a change in the underlying hormonal signal.
Tirzepatide adds activation of the GIP (glucose-dependent insulinotropic polypeptide) receptor, a second metabolic signaling pathway. This dual mechanism is associated with larger average weight reductions in clinical trials.
What the trials show
The STEP 1 trial of semaglutide found an average 14.9% reduction in body weight over 68 weeks compared to 2.4% with placebo. The SURMOUNT-1 trial of tirzepatide found up to 22.5% average weight reduction at the highest dose over 72 weeks. These are clinically meaningful effect sizes — the largest documented for a pharmacological weight-management intervention.
Compounded semaglutide and tirzepatide are not FDA-approved drugs. They are prepared by USA-based licensed 503A compounding pharmacies to a clinician’s specification for individual patients. No hidden overseas supply chain.
Who they suit
GLP-1 agents are clinically indicated for adults with a BMI of 30 or above, or BMI of 27 or above with at least one weight-related health condition. They require a clinician intake to screen for contraindications (including personal or family history of medullary thyroid carcinoma and pancreatitis) and to establish an appropriate starting dose and titration schedule.
Among every peptide marketed for weight loss, only the GLP-1 agonists carry the large-trial evidence to back the claim.
How does sermorelin support body composition?
Sermorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). Rather than introducing exogenous growth hormone directly, sermorelin signals the pituitary to release more of the body’s own growth hormone in the natural pulsatile pattern. This supports the downstream effects of growth hormone on body composition: reduced fat mass, preserved lean mass, and improved recovery.
Sermorelin is not a weight-loss drug in the same sense as GLP-1 agents — it does not suppress appetite or produce the same scale of weight reduction documented in GLP-1 trials. What it does is shift body composition by supporting the growth hormone axis, typically administered as a nightly subcutaneous injection to align with the body’s natural growth hormone release pattern during sleep.
Sermorelin is a compounded peptide available through clinician supervision. It is one of the Tier 1 peptides at PepScribe — prescribed by licensed clinicians and prepared by USA-based 503A pharmacies. Learn more about sermorelin.
Are peptide injections safe? Clinician-supervised vs. unregulated
The safety profile of peptide injection for weight loss is very different depending on the source.
Peptides obtained from unregulated online vendors — often marketed as “research chemicals” — carry significant risks: unknown purity, undisclosed excipients, contamination, inaccurate dosing, and no clinical screening for contraindications. There is no responsible path to injecting compounds from unverified sources.
Compounded peptides prepared by USA-based licensed 503A pharmacies, prescribed by a licensed clinician, carry a fundamentally different risk profile. 503A compounding pharmacies operate under state pharmacy board oversight and USP standards. The clinician intake screens for contraindications. Dosing is individualized. Follow-up monitoring catches emerging issues.
For GLP-1 agents specifically, the main clinical risks include GI side effects (nausea is the most common reason for dose adjustment or discontinuation), rare pancreatitis, and gallbladder issues. These are manageable under proper supervision.
What realistic results can you expect from peptide injections for weight loss?
Peptide injection for weight loss — at least with GLP-1 agents — produces real, meaningful weight reduction in clinical trials. But several realities are worth stating clearly:
- Individual response varies: Trial averages mask significant variation. Some people lose substantially more than the average; some lose less; a small proportion are non-responders.
- Weight regain after stopping: Weight lost on GLP-1 agents largely returns when the medication is discontinued. These treatments appear to work primarily while being taken.
- Lifestyle still matters: GLP-1 agents reduce the drive to overeat — they do not independently optimize nutrition quality, muscle mass, or metabolic health. Resistance training and adequate protein intake matter for body composition outcomes.
- Clinician supervision is not optional: These are not supplements. They are prescription medications that require a proper intake, ongoing monitoring, and clinician availability if issues arise.
Frequently asked questions
What peptide injections are used for weight loss?
The peptides with the strongest clinical evidence for weight loss are GLP-1 receptor agonists — semaglutide and tirzepatide — which suppress appetite and slow gastric emptying. Sermorelin, a growth hormone releasing hormone (GHRH) analogue, is prescribed for body composition support under clinician supervision. Other peptides are used for recovery or hormonal support within clinician-supervised programs.
Do peptide injections for weight loss work?
GLP-1 receptor agonists (semaglutide, tirzepatide) have the most robust clinical trial evidence for weight loss — STEP 1 and SURMOUNT-1 trials documented average reductions of 15-22% of body weight over 68-72 weeks. Sermorelin supports growth hormone secretion and body composition. The evidence varies significantly by peptide — not all peptides studied in weight or body composition contexts have the same evidence base.
Are peptide injections safe for weight loss?
Peptides prescribed by licensed clinicians and compounded by USA-based 503A pharmacies carry a very different risk profile from unregulated research chemicals obtained online. The main safety considerations for GLP-1 peptides are GI side effects (nausea, vomiting), rare pancreatitis risk, and contraindications including personal/family history of medullary thyroid carcinoma. A clinician intake screens for these. Obtaining any peptide from unregulated sources carries serious purity, sterility, and dosing risks.
Do you need a prescription for peptide injections for weight loss?
Yes. Compounded peptides for weight loss require a clinician prescription. A legitimate program involves a clinical intake, potentially labs, and ongoing clinician monitoring. Any website offering injectable peptides for weight loss without a clinician review process is not operating through proper channels.
How are peptide injections administered?
GLP-1 receptor agonists are typically self-administered via subcutaneous injection (into fatty tissue under the skin) once weekly. Injection sites include the abdomen, thigh, or upper arm. Clinicians or nurses review injection technique at intake. Most patients find the injection straightforward after the first use.
What is the difference between semaglutide and tirzepatide for weight loss?
Semaglutide is a GLP-1 receptor agonist. Tirzepatide is a dual GIP/GLP-1 receptor agonist that activates an additional metabolic receptor. Clinical trials show tirzepatide produces larger average weight loss (up to 22% vs roughly 15% for semaglutide), but individual response varies and both require clinician evaluation.